Biopharmaceutical CDMO Capacity Crunch Persists, Driving Rapid Expansion in Cell and Gene Therapy Production

August 17, 2026

Contract Pharma USA

Overview

The biopharmaceutical industry continues to face a CDMO capacity crunch, prompting contract development and manufacturing organizations to heavily invest in expanding production capabilities, particularly for mammalian cell culture systems and cell and gene therapies. As strategic outsourcing becomes paramount, CDMOs differentiate themselves not just by manufacturing slots, but also by their flexibility, technical expertise, responsiveness, and adaptability to evolving programs. This trend is crucial for accelerating the market entry of innovative biopharmaceuticals.

In Depth

Key Findings

The biopharmaceutical manufacturing sector continues to experience a persistent capacity crunch among Contract Development and Manufacturing Organizations (CDMOs). This is largely driven by rapid market growth and surging demand, particularly in cell and gene therapies (CGTs) and mammalian cell culture systems. To address this situation, CDMOs are aggressively investing in facilities and significantly expanding both their technological expertise and production capacities. This capacity expansion is critical for ensuring the rapid delivery of new therapeutic options to patients.

Technical & Clinical Details

Manufacturing biopharmaceuticals—especially monoclonal antibodies, recombinant proteins, and cell and gene therapy products—demands highly specialized expertise and state-of-the-art facilities due to their inherent complexity. The CDMO capacity shortage is primarily exacerbated by:

Increased Demand: A growing pipeline of new biopharmaceuticals and a sharp rise in market demand for approved products.
Technological Diversification: The emergence of diverse modalities like Antibody-Drug Conjugates (ADCs), mRNA vaccines, and CGTs necessitates complex manufacturing processes and specific platform investments.
Lagging Capital Investment: High capital expenditures and the time required for training specialized personnel mean supply struggles to keep pace with demand.

In response, CDMOs are focusing their investments and capacity expansion on the following areas:

Mammalian Cell Culture Capacity: Enhancing large-scale culture systems, particularly those using Chinese Hamster Ovary (CHO) cells. The adoption of single-use technologies improves flexibility and rapid changeover capabilities.
Cell and Gene Therapy Manufacturing: CGT products require individualized manufacturing processes, making aseptic environments, viral vector production, cell processing, and fill-finish operations with specialized equipment and skilled personnel indispensable. Many CDMOs are building or expanding dedicated CGT cleanrooms and process development labs.
Digital Manufacturing and Automation: Implementing automated systems leveraging Process Analytical Technology (PAT), AI, and digital twins aims to streamline manufacturing, enhance quality control, and improve traceability.

These initiatives are transforming CDMOs from mere providers of manufacturing slots into value-added partners throughout the entire product development lifecycle.

Background & Context

For pharmaceutical companies, particularly smaller biotech ventures, constructing and maintaining biopharmaceutical manufacturing facilities presents significant barriers due to enormous investment and specialized expertise requirements. Consequently, outsourcing manufacturing processes to CDMOs has become a strategic choice to mitigate risks, conserve capital, and accelerate development. CDMOs can leverage multiple client projects to maximize facility utilization and accumulate expertise. However, with the explosive growth of the biopharmaceutical market in recent years, CDMO supply capacity has struggled to keep up with demand, leading to a “Capacity Crunch” that is an industry-wide challenge. This issue could delay the market entry of new biopharmaceuticals and impact patient access to treatments.

Strategic Significance & Outlook

While the CDMO capacity crunch is unlikely to resolve in the short term, the industry will enhance its responsiveness through continuous capital investment and technological innovation. Specifically, the following trends are expected to accelerate:

Strategic Partnerships: Long-term strategic partnerships between pharmaceutical companies and CDMOs will become even more crucial.
Technological Innovation and Platformization: Development and adoption of more efficient and flexible manufacturing platforms (e.g., continuous production, single-use technologies) will accelerate, leading to an increase in CDMOs specializing in specific modalities.
Digitalization Drive: Data-driven decision-making and automation will strengthen process optimization and quality assurance.
Global Expansion: Efforts to fortify regional supply chains and expand international manufacturing sites to meet global regulatory requirements will advance.

These trends are essential for supporting the overall growth of the biopharmaceutical industry and ensuring the provision of innovative therapies to patients.

Source: https://www.contractpharma.com/the-cdmo-capacity-crunch-persists/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.